← Human Trials & Peer-Reviewed Studies
Inhibitory effects of cholecystokinin on postprandial gastric myoelectrical activity
Plain-language guide to PMID 8536521 (1995): double-blind controlled clinical trial of Cholecystokinin (CCK) and Sincalide in 10 subjects.
Key Facts
- PMID
- 8536521
- Journal
- Digestive diseases and sciences
- Year
- 1995
- Study type
- Controlled Clinical Trial
- Authors
- Chen JD et al. (4 authors)
- DOI
- 10.1007/BF02220450
What This Study Did, in Plain Language
What Was Tested
Researchers studied Cholecystokinin (CCK) and Sincalide in this controlled clinical trial publication.
The aim of this study was to investigate the effects of intravenous infusion of CCK-8 on gastric myoelectrical activity in normal humans.
Why It Was Studied
While a number of studies have investigated the effects of cholecystokinin (CCK) on gastrointestinal motility, little is known on the effects of CCK on gastric myoelectrical activity, which regulates gastric motility.
The procedure for each session was as follows: (A) 30-min baseline fasting electrogastrogram (EGG); (B) start infusion, another 30-min EGG; (C) give meal, 60-min EGG; and (D) stop infusion, another 60-min EGG.
Who Took Part
The study group was 10 subjects.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
Gastric myoelectrical activity was measured in 10 healthy subjects with a noninvasive electrogastrographic technique by placing abdominal electrodes on the epigastric area.
How the Study Was Run
The researchers set it up as a double-blind and placebo-controlled study.
Blinding on both sides kept the subjects and researchers unaware of who received Cholecystokinin (CCK).
The comparison arm used a placebo, so changes seen with Cholecystokinin (CCK) could be set against what happens without it.
What Was Measured
While a number of studies have investigated the effects of cholecystokinin (CCK) on gastrointestinal motility, little is known on the effects of CCK on gastric myoelectrical activity, which regulates gastric motility.
PubMed files the paper under topics including Eating, Electrodiagnosis, Food, Myoelectric Complex, Migrating, Sincalide and Stomach.
What This Means in Plain Language
The paper is a double-blind and placebo-controlled study of Cholecystokinin (CCK) and Sincalide in 10 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1995 (Digestive diseases and sciences), a journal based in United States.
More context: the Cholecystokinin (CCK) compound page and the Sincalide compound page, all human trials.
Our Notes on the Compounds
Cholecystokinin (CCK): A gut and brain peptide hormone that stimulates gallbladder contraction and signals fullness.
Sincalide: A synthetic 8-amino-acid fragment of cholecystokinin (Kinevac) used in gallbladder and pancreas imaging.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.